Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRL54443 is a **synthetic small molecule** of the piperidinylindole class that acts as a **potent and selective agonist** at the serotonin **5-HT1E and 5-HT1F receptors**. It exhibits over 30-fold selectivity for these receptors compared to other 5-HT and dopamine receptor subtypes. In preclinical studies, BRL54443 has been shown to hyperpolarize neurons by increasing steady-state, depolarization-activated potassium currents, potentially involving voltage-gated potassium channels. It is primarily used as a research tool and is not approved for medical use. Its effects have been studied in behavioral and electrophysiological assays in animal models, including reduced locomotor activity in rats and dose-dependent actions on gastrointestinal function in cats[1][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BRL54443.